Bayer and Cedilla Therapeutics Partner to Develop Targeted Cancer Therapies

Bayer and Cedilla Therapeutics Partner to Develop Targeted Cancer Therapies

Not intended UK Media

(IN BRIEF) Bayer and Cedilla Therapeutics have entered into an exclusive license agreement to develop and commercialize Cedilla’s CyclinE1/CDK2 complex inhibitors for precision oncology. These inhibitors target oncogenic drivers and offer a unique method of action, allowing for precise targeting in patients with high unmet medical needs. Under the agreement, Bayer will have full rights for development and commercialization, while Cedilla will receive upfront and milestone payments, as well as royalties on commercialized medicines. The collaboration strengthens Bayer’s early pipeline in precision oncology and emphasizes their commitment to innovative therapies for cancer patients.

(PRESS RELEASE) BERLIN/ BOSTON, 1-Jun-2023 — /EuropaWire/ — Bayer (ETR: BAYN), a global enterprise with core competencies in the life science fields of healthcare and nutrition and and one of the largest pharmaceutical companies in the world, and Cedilla Therapeutics, a pioneering biotechnology company in the field of precision oncology, have entered into an exclusive license agreement. The partnership aims to develop and commercialize Cedilla Therapeutics’ CyclinE1/CDK2 complex inhibitors, which target specific oncogenic drivers.

In various cancers, the overexpression or genetic activation of cyclin E, a binding partner of Cyclin Dependent Kinase 2 (CDK2), plays a significant role in the oncogenic process. Cedilla’s small molecules uniquely modulate the protein complex, resulting in highly selective inhibition. This novel approach allows for precise targeting of patients with high unmet medical needs, potentially improving safety and efficacy compared to standard treatment options.

As per the agreement, Bayer will gain exclusive rights for the development and commercialization of Cedilla’s CyclinE1/CDK2 complex inhibitors. In exchange, Cedilla will receive an upfront payment, milestone payments based on development and commercial achievements, and royalties on any technology-based medicines brought to market by Bayer. The financial terms of the agreement remain undisclosed.

This collaboration further strengthens Bayer’s early pipeline in precision oncology and demonstrates the company’s commitment to advancing innovative therapies for patients with unmet medical needs. By leveraging Cedilla’s breakthrough discoveries in targeting oncogenic drivers, Bayer aims to provide new treatment options that can make a significant difference in the lives of cancer patients.

“We are excited to bring these highly innovative preclinical programs in-house that complement our early pipeline in precision oncology,” said Dominik Ruettinger, M.D., Ph.D., Global Head of Research and Early Development for Oncology, Pharmaceuticals Division, Bayer AG. “We look forward to progressing Cedilla’s programs and continuing to focus on assets that allow better patient selection. With our oncology strategy, we are dedicated to accelerating the research and development of novel cancer therapies that have the potential to make a meaningful difference in the lives of patients.”

“Cedilla is proud to partner with Bayer on this exciting program,” said Neil Exter, Chief Executive Officer of Cedilla Therapeutics and Partner at Third Rock Ventures. “Cedilla’s bespoke molecules are designed to inhibit oncogenic drivers, only in their functionally relevant context, thereby unlocking wider therapeutic window and potentially greater efficacy, for targets that are critical and elusive.”

About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2022, the Group employed around 101,000 people and had sales of 50.7 billion euros. R&D expenses before special items amounted to 6.2 billion euros. For more information, go to

Find more information at
Follow us on Facebook:
Follow us on Twitter: @BayerPharma

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Media contact:

Dr. Imke Meyer
External Innovation and Partnering
+49 214-600-01275




Comments are closed.